Gimeno-Gracia Mercedes, Crusells-Canales María José, Rabanaque-Hernández María José
Pharmacy Department, "Lozano Blesa" University Clinical Hospital, c/San Juan Bosco, 50009, Saragossa, Spain,
Int J Clin Pharm. 2014 Dec;36(6):1190-5. doi: 10.1007/s11096-014-0015-x. Epub 2014 Sep 25.
The number of Human Immunodeficiency Virus (HIV) patients aged 50 years or over is growing year on year, due to both late diagnoses and the chronicity of the illness. This increase is a new phenomenon.
To describe the clinical and epidemiological characteristics of the older HIV infected population and determine if there are differences in antiretroviral treatment between younger and older patients.
This study was conducted in the outpatient hospital pharmacy service of a University Hospital in Spain.
A descriptive study involving HIV infected patients aged 50 years or older who received ambulatory antiretroviral therapy between January and December 2011. Variables related to HIV and to antiretroviral therapy were collected. A comparison of antiretroviral drugs used was made with the populations older and younger than 50 years.
Antiretroviral therapy differences between older and younger HIV-patients.
130 patients (20% of the antiretroviral treated patients) were 50 or over and 77% of these was aged between 50 and 59. At the time of diagnosis, 50% suffered an advanced state of disease. At the end of the study period, 58% had CD4 lymphocyte levels of over 500 cells/mm(3) and 90% had an undetectable viral load. The antiretroviral therapy of the older group that was based on protease inhibitors was used in the 51.5% of the patients compared with 54.4% in the younger group. The figures for nonnucleoside reverse transcriptase inhibitors based therapy were 43.8 and 39.8%, respectively. The older population used treatments that included tenofovir (56.9 vs. 64.8%, p = 0.105) less frequently and used more treatments that included abacavir (26.9 vs. 19.1%, p = 0.054) than the under 50's.
Half the older HIV-infected patients were diagnosed with an advanced disease and the majority showed a positive response to antiretroviral therapy. There are no statistically significant differences between the frequency of antiretroviral therapy use in older and younger HIV-patients, although older HIV-patients has less often used treatments with tenofovir and more often used treatments with abacavir.
由于诊断延迟和疾病的慢性化，50岁及以上的人类免疫缺陷病毒（HIV）患者数量逐年增加。这种增长是一个新现象。
描述老年HIV感染人群的临床和流行病学特征，并确定年轻患者和老年患者在抗逆转录病毒治疗方面是否存在差异。
本研究在西班牙一家大学医院的门诊药房进行。
一项描述性研究，涉及2011年1月至12月期间接受门诊抗逆转录病毒治疗的50岁及以上HIV感染患者。收集与HIV和抗逆转录病毒治疗相关的变量。将使用的抗逆转录病毒药物与50岁及以上和50岁以下人群进行比较。
老年和年轻HIV患者之间的抗逆转录病毒治疗差异。
130名患者（占接受抗逆转录病毒治疗患者的20%）年龄在50岁及以上，其中77%年龄在50至59岁之间。在诊断时，50%的患者处于疾病晚期。在研究期结束时，58%的患者CD4淋巴细胞水平超过500个细胞/mm³，90%的患者病毒载量检测不到。老年组基于蛋白酶抑制剂的抗逆转录病毒治疗在51.5%的患者中使用，而年轻组为54.4%。基于非核苷类逆转录酶抑制剂治疗的数字分别为43.8%和39.8%。与50岁以下人群相比，老年人群使用替诺福韦的治疗（56.9%对64.8%，p = 0.105）频率较低，使用阿巴卡韦的治疗（26.9%对19.1%，p = 0.054）频率较高。
一半的老年HIV感染患者被诊断为晚期疾病，大多数患者对抗逆转录病毒治疗有阳性反应。老年和年轻HIV患者在抗逆转录病毒治疗使用频率上没有统计学上的显著差异，尽管老年HIV患者使用替诺福韦治疗的频率较低，使用阿巴卡韦治疗的频率较高。
